Related Experiment Video
Updated: Sep 12, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Long-Acting In Situ Cancer Vaccines by Oncolytic STING-Activating Microgels
Hujing Tan1, Jiakun Guo1, Yan Wang1
1Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Materials, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, China.
Abstract:
In situ cancer vaccines exploiting endogenous multiple antigens directly from tumors to elicit broad immune responses hold great potential in cancer treatment. However, the feeble antigen presentation and hostile immune microenvironments pose severe challenges to acquiring clinical benefits. Here, oncolytic STING-activating microgels (OSAM) that release oncolytic peptide LTX-315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long-acting and powerful antitumor immunity. OSAM induced significant upregulation of MHC I and substantial activation of dendritic cells for more than one week. One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti-CTLA-4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%-71%. These oncolytic STING-activating microgels introduce a new and powerful strategy to in situ cancer vaccines.
Insights
New oncolytic STING-activating microgels (OSAM) deliver cancer-fighting agents LTX-315 and diABZI. This sustained release strategy enhances antitumor immunity and T-cell infiltration for effective cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biomaterials Science
Background:
- In situ cancer vaccines leverage tumor antigens for broad immune responses.
- Challenges include poor antigen presentation and immunosuppressive tumor microenvironments.
Purpose of the Study:
- To develop oncolytic STING-activating microgels (OSAM) for sustained release of LTX-315 and diABZI.
- To evaluate OSAM's efficacy in eliciting long-acting antitumor immunity.
Main Methods:
- Developed OSAM for sustained release (>4 weeks) of oncolytic peptide LTX-315 and STING adjuvant diABZI.
- Assessed MHC I upregulation and dendritic cell activation.
- Investigated immune cell infiltration (T cells, NK cells) in murine tumor models.
Main Results:
- OSAM significantly upregulated MHC I and activated dendritic cells for over a week.
- Single intratumoral OSAM administration promoted cytotoxic T lymphocyte and natural killer cell infiltration.
- Combination therapy with anti-CTLA-4 microgels achieved cure rates of 40%-71% in murine models.
Conclusions:
- OSAM provides a novel strategy for potent, long-acting in situ cancer vaccination.
- Sustained release of oncolytic agents and adjuvants enhances antitumor immunity.
- Combination therapy demonstrates significant therapeutic potential in preclinical cancer models.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy